Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)

J Neurooncol. 2019 Jul;143(3):583. doi: 10.1007/s11060-019-03201-3.

¹ Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. [email protected].
² Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
³ Mayo Clinic Rochester, Rochester, MN, USA.
⁴ University of Pittsburgh, Pittsburgh, PA, USA.
⁵ , Metro-Minnesota, St. Louis Park, MN, USA.

Abstract

The last author's first name was truncated in the initial online publication. The original article has been corrected.